Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 3 5Phase 1/2 4Phase 2/3 3Phase 1 2Phase NA 1Phase 4 1

Status

Completed 31Recruiting 25Active not recruiting 20Terminated 8Not yet recruiting 5Unknown 4Withdrawn 1Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic cancer, adult 1Pancreatic Neoplasms 1Pancreatic Cancer Resectable 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 24Capecitabine 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Carboplatin 18Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Injections 10Pemetrexed 9Bevacizumab 9Specimen Handling 8Radiation 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × 130-nm albumin-bound paclitaxel × Clear all
NCT07524257 2026-05-04

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

ImmunityBio, Inc.

Phase 3 Not yet recruiting
494 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
106 enrolled
Gastrointestinal

Pancreatic cancer, adult

NCT07272109 2025-12-15

PTCA199-16

Fudan University

Phase 3 Not yet recruiting
210 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Shanghai Henlius Biotech

Phase 3 Not yet recruiting
522 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡